Literature DB >> 14362439

Cycloserine, a new antibiotic, in the treatment of human pulmonary tuberculosis: a preliminary report.

I G EPSTEIN, K G NAIR, L J BOYD.   

Abstract

Entities:  

Keywords:  ANTIBIOTICS/therapeutic use; TUBERCULOSIS, PULMONARY/therapy

Mesh：

Substances：

Year:  1955        PMID： 14362439

Source DB:  PubMed          Journal:  Antibiotic Med Clin Ther (New York)        ISSN： 0570-3107


× No keyword cloud information.
  5 in total

1.  Reducing the toxicity of tubazid by administering it in combination with cycloserine.

Authors:  N I SMOL'NIKOVA
Journal:  Biull Eksp Biol Med       Date:  1962-02

Review 2.  Natural products, small molecules, and genetics in tuberculosis drug development.

Authors:  Maria-Teresa Gutierrez-Lugo; Carole A Bewley
Journal:  J Med Chem       Date:  2008-04-05       Impact factor: 7.446

3.  Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China.

Authors:  Yang Li; Fei Wang; Limin Wu; Min Zhu; Guiqing He; Xinchang Chen; Feng Sun; Qihui Liu; Xiaomeng Wang; Wenhong Zhang
Journal:  Infect Drug Resist       Date:  2019-03-29       Impact factor: 4.003

4.  Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China.

Authors:  Jing Wang; Yu Pang; Wei Jing; Wei Chen; Ru Guo; Xiqin Han; Limin Wu; Guangxu Yang; Kunyun Yang; Cong Chen; Lin Jiang; Chunkui Cai; Zhi Dou; Lijuan Diao; Hongqiu Pan; Jianyun Wang; Feifei Du; Tao Xu; Lixia Wang; Renzhong Li; Naihui Chu
Journal:  Infect Drug Resist       Date:  2019-04-03       Impact factor: 4.003

Review 5.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.